MaaT Pharma: share price rises, EMA back in favor

(CercleFinance.com) - MaaT Pharma shares rose on Wednesday morning after receiving a positive opinion from the pediatric committee of the European Medicines Agency (EMA) as part of a pediatric investigation plan for its experimental treatment of graft-versus-host disease.


The EMA's expert committee has approved the clinical program to evaluate the safety and efficacy of MaaT013 in patients aged from six to under 18.

This means that a single-arm clinical trial for third-line treatment in 18 pediatric patients with acute graft-versus-host disease (aGvH) can be initiated in 2026.

With this regulatory milestone now achieved, MaaT says it is 'well on track' to submit a marketing authorization application to the EMA in June 2025.

The pressing issue now is to obtain additional financing, as the company's cash position (as at September 24) only allowed it to cover its needs until the second quarter of 2025", Stifel's analysts noted this morning.

On the Paris Bourse, MaaT Pharma's share price rose by almost 4% on Wednesday morning in the wake of this announcement.

Copyright (c) 2025 CercleFinance.com. All rights reserved.